Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      Sub Lingual Immunotherapy
      loading

      Chapter

      Sub Lingual Immunotherapy

      DOI link for Sub Lingual Immunotherapy

      Sub Lingual Immunotherapy book

      Sub Lingual Immunotherapy

      DOI link for Sub Lingual Immunotherapy

      Sub Lingual Immunotherapy book

      ByParanjothy Kanni, Nagendra Prasad Komarla, A. B. Singh
      BookAllergy and Allergen Immunotherapy

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 2017
      Imprint Apple Academic Press
      Pages 14
      eBook ISBN 9781315207520
      Share
      Share

      ABSTRACT

      Allergy is on the increase worldwide. Today people are becoming more and more aware about the allergens and the Sublingual Immunotherapy (SLIT). Allergens are molecules with capacity to elicit IgE responses in human (reactive antibodies induce allergy symptoms). Identifying causative allergens and feeding allergy subjects in small quantities through Sublingual route (SLIT) on daily basis over a period of time induce tolerance in the body by producing blocking antibodies (IgG), which reduces

      the allergy symptoms. Sublingual immunotherapy emerged in the year 1980 in the midst of safety issues of traditional century old subcutaneous immunotherapy (SCIT). Study by Scadding and Brostoff introducing Sublingual immunotherapy (SLIT) with very low doses and followed by another controlled trial after a gap of four years. A major turn on first metaanalysis evaluating the data from the first 22 controlled studies, demonstrated the efficacy and safety of SLIT in seasonal allergic rhinitis. Now, the studies of dose-response clearly demonstrate that the clinical efficacy of SLIT depends upon the administrated dosage, as already proved since long time for SCIT. Systematic revision of the literature showed that SLIT has no dose dependence of safety, which allowed the development of new formulations of SLIT without up dosing phase. SLIT is considered a suitable alternative to injections.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited